安杰思：股东新建元减持公司股份约35万股，本次减持计划结束

Group 1 - The core point of the news is that Anjisi (SH 688581) announced the completion of a share reduction plan by its shareholder, Xinjianyuan, who reduced approximately 350,000 shares, accounting for 0.427% of the total share capital [1] - As of October 23, 2025, Xinjianyuan reduced shares through centralized bidding, totaling about 350,000 shares, with no shares reduced through block trading [1] - For the year 2024, Anjisi's revenue composition is heavily weighted towards medical devices, which account for 99.41% of total revenue, while other businesses contribute only 0.59% [1] Group 2 - As of the latest report, Anjisi's market capitalization stands at 5.3 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing deals, totaling $80 billion this year, indicating a robust secondary market for biomedicine [2] - Despite the hot secondary market, the primary market for fundraising in the biomedicine sector is experiencing a cooling trend, as noted by a partner at a venture capital firm [2]